1. Home
  2. SCYX vs MNY Comparison

SCYX vs MNY Comparison

Compare SCYX & MNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • MNY
  • Stock Information
  • Founded
  • SCYX 1999
  • MNY 2014
  • Country
  • SCYX United States
  • MNY Singapore
  • Employees
  • SCYX N/A
  • MNY N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • MNY
  • Sector
  • SCYX Health Care
  • MNY
  • Exchange
  • SCYX Nasdaq
  • MNY Nasdaq
  • Market Cap
  • SCYX 28.5M
  • MNY 31.9M
  • IPO Year
  • SCYX 2014
  • MNY N/A
  • Fundamental
  • Price
  • SCYX $0.74
  • MNY $1.50
  • Analyst Decision
  • SCYX
  • MNY Strong Buy
  • Analyst Count
  • SCYX 0
  • MNY 1
  • Target Price
  • SCYX N/A
  • MNY $4.00
  • AVG Volume (30 Days)
  • SCYX 188.8K
  • MNY 517.5K
  • Earning Date
  • SCYX 08-07-2025
  • MNY 06-13-2025
  • Dividend Yield
  • SCYX N/A
  • MNY N/A
  • EPS Growth
  • SCYX N/A
  • MNY N/A
  • EPS
  • SCYX N/A
  • MNY N/A
  • Revenue
  • SCYX $2,630,000.00
  • MNY $71,649,746.00
  • Revenue This Year
  • SCYX $410.22
  • MNY $16.97
  • Revenue Next Year
  • SCYX $248.83
  • MNY $19.35
  • P/E Ratio
  • SCYX N/A
  • MNY N/A
  • Revenue Growth
  • SCYX N/A
  • MNY N/A
  • 52 Week Low
  • SCYX $0.66
  • MNY $0.55
  • 52 Week High
  • SCYX $2.28
  • MNY $1.88
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 46.93
  • MNY 75.86
  • Support Level
  • SCYX $0.67
  • MNY $0.99
  • Resistance Level
  • SCYX $0.83
  • MNY $1.10
  • Average True Range (ATR)
  • SCYX 0.05
  • MNY 0.18
  • MACD
  • SCYX 0.01
  • MNY 0.06
  • Stochastic Oscillator
  • SCYX 47.06
  • MNY 68.85

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About MNY MoneyHero Limited

MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.

Share on Social Networks: